US Patent

US9044480 — Compositions and methods for treating HCV

Method of Use · Assigned to AbbVie Inc · Expires 2031-04-10 · 5y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of using Compound I to treat certain types of HCV patients, including those with specific genetic characteristics.

USPTO Abstract

The present invention features methods of using Compound I to suppress HCV mutants, treat treatment-experienced HCV patients, and treat HCV patients having non-CC IL28B rs12979860 genotype.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1638`	—
`U-1638`	—
`U-1638`	—

Patent Metadata

Patent number: US9044480
Jurisdiction: US
Classification: Method of Use
Expires: 2031-04-10
Drug substance claim: No
Drug product claim: No
Assignee: AbbVie Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.